InsidersTradesSigma
Total declarations
Company
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
13
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-40.0%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Hoffman Michael B, Director. Officer active across 1 company, notably Annovis Bio, Inc.. Cumulatively, 21 reports have been logged. Split: 13 buys · 0 sell. Total volume traded: €3.5m. History available since 4 January 2022. The latest transaction was disclosed on 20 May 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Hoffman Michael B
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
2,562 shares@ US$1.750.0041% mcap0.1% of flowCommon StockSEC:0001104659-26-065311:0
Canonical exit: 18 Aug 2026 (T+90)
18,849 shares@ US$1.800.031% mcap1.0% of flowCommon StockSEC:0001104659-26-065311:1
Canonical exit: 18 Aug 2026 (T+90)
54,933 shares@ US$1.89990.095% mcap3.0% of flowCommon StockSEC:0001104659-26-065311:2
Canonical exit: 18 Aug 2026 (T+90)
713,800 shares@ US$2.1029.9% of flowCommon StockSEC:0001104659-26-039675:0
Canonical exit: 1 Jul 2026 (T+90)
30,000 shares@ US$4.33981.8% of flowCommon StockSEC:0001104659-25-119407:0
Canonical exit: 8 Mar 2026 (T+90)
1,489 shares@ US$4.130.2% of flowCommon StockSEC:0001104659-25-115801:0
Canonical exit: 22 Feb 2026 (T+90)
9,200 shares@ US$3.851.0% of flowCommon StockSEC:0001104659-25-115801:1
Canonical exit: 22 Feb 2026 (T+90)
415 shares@ US$4.140.0% of flowCommon StockSEC:0001104659-25-115801:2
Canonical exit: 22 Feb 2026 (T+90)
28,096 shares@ US$4.153.3% of flowCommon StockSEC:0001104659-25-115801:3
Canonical exit: 22 Feb 2026 (T+90)
1,489 shares@ US$4.130.1% of flowCommon StockSEC:0001104659-25-116084:0
Canonical exit: 22 Feb 2026 (T+90)
10,000 shares@ US$3.490.5% of flowCommon StockSEC:0001104659-25-115090:0
Canonical exit: 19 Feb 2026 (T+90)
15,000 shares@ US$2.110.9% of flowCommon StockSEC:0001104659-25-113459:0
Canonical exit: 12 Feb 2026 (T+90)
975,610 shares@ US$2.0528.4% of flowCommon StockSEC:0001104659-25-109905:0
Canonical exit: 26 Jan 2026 (T+90)
5,000 shares@ US$2.280.2% of flowCommon StockSEC:0001104659-25-087077:0
6,717 shares@ US$2.600.3% of flowCommon StockSEC:0001104659-25-080981:0
25,000 shares@ US$2.801.4% of flowCommon StockSEC:0001104659-25-059897:0
5,000 shares@ US$2.430.3% of flowCommon StockSEC:0001104659-25-055487:0
163,880 shares@ US$6.1030.1% of flowCommon StockSEC:0001104659-23-120764:0
164,745 shares@ US$6.0730.1% of flowCommon StockSEC:0001104659-23-120304:0
59,477 shares@ US$12.6122.6% of flowCommon StockSEC:0001104659-23-044204:0
30,000 shares@ US$4.390.12% mcap50.0% of flowCommon StockSEC:0001104659-22-001638:0
21 of 21 declarations
About Hoffman Michael B
Michael B. Hoffman is a Director at Annovis Bio, Inc. He contributes to the governance of the company by providing his expertise and strategic advice. His role on the board is crucial for guiding decisions and supporting the growth of Annovis Bio.
